Abstract
Angiotensin-converting enzyme inhibitors (ACE-I) reduce proteinuria and protect the kidney in proteinuric renal disease. During ACE-I therapy, circulating levels of angiotensin (1-7) [Ang (1-7)] are increased. As cardiac and renal protective effects of Ang (1-7) have been reported, we questioned whether Ang (1-7) contributes to the antiproteinuric effects of ACE-I treatment.
Therefore, we evaluated whether Ang (1-7) infusion reduces proteinuria in a rat model of adriamycin-induced renal disease. In addition, the effect of a selective Ang (1-7) blocker, [D-Ala(7)]-Ang (1-7) (A779), was investigated in rats treated with the ACE-1, lisinopril (LIS).
Six weeks after induction of proteinuria, therapy was started in four different groups: control, Ang (1-7), LIS, and LIS+A779. After two weeks, the rats were sacrificed. Six weeks after injection of adriamycin, the rats had developed proteinuria of 323 +/- 40 mg/24 hours. The proteinuria remained stable in the control group and in the Ang (1-7) group, but was reduced in both LIS and LIS+A779-treated groups. Similarly, blood pressure (BP) was unchanged in the control and the Ang (1-7) groups, but reduced in both the LIS and the LIS+A779 groups. Plasma levels of Ang (1-7) were increased in the Ang (1-7) and in both LIS-treated groups.
We conclude that systemic Ang (1-7) plays no major role in the antiproteinuric and BP-lowering effects of ACE-I in this rat model of adriamycin-induced nephrosis.
Original language | English |
---|---|
Pages (from-to) | 96-101 |
Number of pages | 6 |
Journal | Journal of the Renin-Angiotensin-Aldosterone System |
Volume | 6 |
Issue number | 2 |
DOIs | |
Publication status | Published - Sept-2005 |
Keywords
- angiotensin (1-7)
- ACE-inhibitors
- proteinuria
- BP
- ESTABLISHED ADRIAMYCIN NEPHROSIS
- CONVERTING-ENZYME-INHIBITORS
- HEART-FAILURE
- NATRIURETIC ACTION
- HYPERTENSIVE-RATS
- SYSTEM
- ANTAGONIST
- BRADYKININ
- CARBOXYPEPTIDASE
- PROTEINURIA